Archives of Dermatological Research

, Volume 310, Issue 3, pp 255–259 | Cite as

BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid

  • Maryam Daneshpazhooh
  • Maryam Ghiasi
  • Vahideh Lajevardi
  • Nafise Nasiri
  • Kamran Balighi
  • Amir Teimourpour
  • Hasan Khosravi
  • Vahide Saeidi
  • Hamidreza Mahmoudi
  • Cheyda Chams-Davatchi
Concise Communication


Bullous pemphigoid (BP) is an autoimmune bullous disease characterized by autoantibody production against BP180 and BP230. Two scoring systems have been validated for BP including: Bullous Pemphigoid Disease Area Index (BPDAI) and Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). In this study, we investigated correlations between both scoring systems and either anti-BP180 NC16A or anti-BP230 values. BPDAI and ABSIS were used to measure disease activity in 95 BP patients at Razi Hospital in Tehran, Iran. ELISA was performed on patient sera to identify any significant relationship between anti-BP180 NC16A/anti-BP230 values and BP disease activity. The two scores showed a strong correlation (ρ = 0.73; p value < 0.0001). Anti-BP180 NC16A values correlated with BPDAI (ρ = 0.49, p value = 0.0001), ABSIS (ρ = 0.47, p value < 0.0001), and BPDAI-Pruritus scores (ρ = 0.29, p value < 0.005). There was a strong correlation between anti-BP180 NC16A values and the ABSIS Skin score (ρ = 0.58, p value < 0.0001), and a moderate correlation with erosion/blister BPDAI score (ρ = 0.48, p value < 0.001) and urticaria/erythema BPDAI score (ρ = 0.27, p value = 0.009). Anti-BP230 values did not demonstrate any relationship with either scores or their subcomponents. Both scoring systems demonstrated moderate validity. Mucosal components did not show any correlation with anti-BP antibodies and are disproportionately presented in both BP scoring tools.


Bullous Pemphigoid Disease Area Index Autoimmune Bullous Skin Disorder Intensity Score Anti-BP180 NC16A Anti-BP230 Bullous pemphigoid 


Author contributions

All listed authors are qualified for authorship, had access to the data, and have participated in the preparation of the manuscript.


The study has received a grant from Tehran University of Medical Sciences, and it is approved by the institutional review board of Tehran University of Medical Sciences. This research has been supported by Tehran University of Medical Sciences and Health Services Grant number 94-01-101-27529.

Compliance with ethical standards

Conflict of interest

To the authors’ knowledge, no conflict of interest, financial or other exists.

Ethical approval

The institutional review board of Tehran University of Medical Sciences has approved this study.

Informed consent

Patients gave informed consent.


  1. 1.
    Bernard P, Bedane C, Bonnetblanc JM (1997) Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol 136:694–698CrossRefPubMedGoogle Scholar
  2. 2.
    Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Steven SR, Chen M, Fairley JA, Woudley DT, Miller SD, Gordon KB (1998) Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 110:103–109CrossRefPubMedGoogle Scholar
  3. 3.
    Daneshpazhooh M, Chams-Davatchi C, Payandemehr P, Nassiri S, Valikhani M, Safai-Naraghi Z (2012) Spectrum of autoimmune bullous diseases in Iran: a 10-year review. Int J Dermatol 51:35–41CrossRefPubMedGoogle Scholar
  4. 4.
    Di Zenzo G, Thoma-Uszynski S, Calabresi V, Fontao L, Hofmann SC, Lacour JP, Sera F, Bruckner-Tuderman L, Zambruno G, Borradori L, Hertl M (2011) Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol 131:2271–2280CrossRefPubMedGoogle Scholar
  5. 5.
    Hashimoto T, Ohzono A, Teye K et al (2017) Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. Br J Dermatol 177(1):141–151CrossRefPubMedGoogle Scholar
  6. 6.
    Ishiura N, Fujimoto M, Watanabe R, Nakashima H, Kuwano Y, Yazawa N, Echigo T, Okochi H, Tamaki K (2008) Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 49:153–161CrossRefPubMedGoogle Scholar
  7. 7.
    Lee EH, Kim YH, Kim S, Kim SE, Kim SC (2012) Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid. Ann Dermatol 24:45–55CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Le Sache-de Peufeilhoux L, Ingen-Housz-Oro S, Hue S, Sbidian E, Valeyrie-Allanore L, Ortonne N, Roujeau JC, Wolkenstein P, Chosidow O, André C (2012) The value of BP230 enzyme-linked immunosorbent assay in the diagnosis and immunological follow-up of bullous pemphigoid. Dermatology 224:154–159CrossRefPubMedGoogle Scholar
  9. 9.
    Levy-Sitbon C, Barbe C, Plee J, Goeldel AL, Antonicelli F, Reguiaï Z, Jolly D, Grange F, Bernard P (2014) Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients. Dermatology 229:116–122CrossRefPubMedGoogle Scholar
  10. 10.
    Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, Caux F, Marinovic B, Sinha AA, Hertl M, Bernard P, Sirois D, Cianchini G, Fairley JA, Jonkman MF, Pandya AG, Rubenstein D, Zillikens D, Payne AS, Woodley D, Zambruno G, Aoki V, Pincelli C, Diaz L, Hall RP, Meurer M, Mascaro JM Jr, Schmidt E, Shimizu H, Zone J, Swerlick R, Mimouni D, Culton D, Lipozencic J, Bince B, Grando SA, Bystryn JC, Werth VP (2012) Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 66:479–485CrossRefPubMedGoogle Scholar
  11. 11.
    Patsatsi A, Kyriakou A, Pavlitou-Tsiontsi A, Giannakou A, Sotiriadis D (2012) Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid. Clin Dev Immunol 2012:854795CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Pfutze M, Niedermeier A, Hertl M, Eming R (2007) Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol 17:4–11PubMedGoogle Scholar
  13. 13.
    Vaillant L, Bernard P, Joly P, Prost C, Labeille B, Bedane C, Arbeille B, Thomine E, Bertrand P, Lok C, Roujeau JC (1998) Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol 134:1075–1080CrossRefPubMedGoogle Scholar
  14. 14.
    van Beek N, Lüttmann N, Huebner F, Recke A, Karl I, Schulze FS, Zillikens D, Schmidt E (2017) Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol 153:30–38CrossRefPubMedGoogle Scholar
  15. 15.
    Wijayanti A, Zhao CY, Boettiger D, Chiang YZ, Ishii N, Hashimoto T, Murrell DF (2017) The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use? Acta Derm Venereol 96:24–31CrossRefGoogle Scholar
  16. 16.
    Zhao CY, Murrell DF (2015) Outcome measures for autoimmune blistering diseases. J Dermatol 42:31–36CrossRefPubMedGoogle Scholar
  17. 17.
    Zhou XP, Liu B, Xu Q, Yang Y, He CX, Zuo YG, Liu YH (2016) Serum levels of immunoglobulins G1 and G4 targeting the non-collagenous 16A domain of BP180 reflect bullous pemphigoid activity and predict bad prognosis. J Dermatol 43:141–148CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Maryam Daneshpazhooh
    • 1
  • Maryam Ghiasi
    • 1
  • Vahideh Lajevardi
    • 1
  • Nafise Nasiri
    • 1
  • Kamran Balighi
    • 1
  • Amir Teimourpour
    • 2
  • Hasan Khosravi
    • 3
  • Vahide Saeidi
    • 1
  • Hamidreza Mahmoudi
    • 1
  • Cheyda Chams-Davatchi
    • 1
  1. 1.Autoimmune Bullous Diseases Research Center, Razi HospitalTehran University of Medical SciencesTehranIran
  2. 2.Department of Epidemiology and Biostatistics, School of Public HealthTehran University of Medical SciencesTehranIran
  3. 3.Harvard Medical SchoolBostonUSA

Personalised recommendations